MUC1 and breast cancer: While HER2 is perhaps the most widely investigated TAA identified in BC, other TAAs, e.g., MUC1, mammaglobin-A, lactalbumin, NY-ESO-1, MAGE, and MART-1, have garnered interest as potential therapeutic targets and have been reviewed comprehensively before (Criscitiello, 2012 #12430).